[1R,3S,7S,10R,11S,12S,16S]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-[2-methylthiazol-4-yl]prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione | 193071-75-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: [1R,3S,7S,10R,11S,12S,16S]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-[2-methylthiazol-4-yl]prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
• 英文别名: 12,13-bisepi-epothilone A；(1R,3S,7S,10R,11S,12S,16S)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
• CAS: 193071-75-9
• 化学式: C₂₆H₃₉NO₆S
• 分子量: 493.665
• InChiKey: HESCAJZNRMSMJG-BPUUBGLZSA-N

物化性质

• 沸点：
  683.3±55.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  34
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  [1R,3S,7S,10R,11S,12S,16S]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-[2-methylthiazol-4-yl]prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione 在 sodium azide 、 氯化铵 作用下， 以 乙醇 为溶剂， 以55%的产率得到[4S-[4R*,7S*,8R*,9R*,13S*,14S*,16R*(E)]]-13-Azido-4,8,14-trihydroxy-5,5,7,9-tetramethyl-16-[1-methyl-2(2-methyl-4-thiazolyl)ethenyl]-1-oxacyclohexadecane-2,6-dione
  参考文献：
  名称：

  Synthesis and Biological Activity of Novel Epothilone Aziridines

  摘要：

  [GRAPHICS]A series of 12 alpha ,13 alpha -aziridinyl epothilone derivatives were synthesized in an efficient manner from epothilone A. The final semisynthetic route involves a formal double-inversion of stereochemistry at both the C12 and C13 positions. All aziridine analogues were tested for effects on tubulin binding polymerization and cytotoxicity. The results indicate that the aziridine moiety is a viable isosteric replacement for the epoxide in the case of epothilones.

  DOI：

  10.1021/ol016273w
• 作为产物：
  描述：

  (1E,3Z)-1-甲氧基-2-甲基-3-(三甲基硅氧基)-1,3-戊二烯 在 RuBnCl₂(PCy₃)2 吡啶 、 咪唑 、 2,6-二甲基吡啶 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 N-碘代丁二酰亚胺 、 lithium aluminium tetrahydride 、 草酰氯 、 偶氮二异丁腈 、 camphor-10-sulfonic acid 、 diethylzinc 、 三正丁基氢锡 、 二甲基二环氧乙烷 、 四氯化钛 、 戴斯-马丁氧化剂 、 氟化氢吡啶 、 di(1H-imidazol-2-yl)methanethione 、 二甲基亚砜 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 [双(三氟乙酰氧基)碘]苯 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 苯 为溶剂， 反应 39.0h， 生成 [1R,3S,7S,10R,11S,12S,16S]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-[2-methylthiazol-4-yl]prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
  参考文献：
  名称：

  Total Syntheses of Epothilones A and B

  摘要：

  Convergent, stereocontrolled total syntheses of the microtubule-stabilizing macrolides epothilones A (2) and B (3) have been achieved. Four distinct ring-forming strategies were pursued (see Scheme 1). Of these four, three were reduced to practice. In one approach, the action of a base on a substance possessing an acetate ester and a nonenolizable aldehyde brought about a remarkably effective macroaldolization see (89 --> 90 + 91; 99 --> 100 + 101), simultaneously creating the C2-C3 bond and the hydroxyl-bearing stereocenter at C-3. Alternatively, the 16-membered macrolide of the epothilones could be fashioned through a C12-C13 ring-closing olefin metathesis (e.g. see 111 --> 90 + 117; 122 --> 105 + 123) and through macrolactonization of the appropriate hydroxy acid (e.g. see 88 --> 93). The application of a stereospecific B-alkyl Suzuki coupling strategy permitted the establishment of a cis C12-C13 olefin, thus setting the stage for an eventual site-and diastereoselective epoxidation reaction (see 96 --> 2; 106 --> 3). The development of a novel cyclopropane solvolysis strategy for incorporating the geminal methyl groups of the epothilones (see 39 --> 40 --> 41), and the use of Lewis acid catalyzed diene-aldehyde cyclocondensation (LACDAC) (see 35 + 36 --> 37) and asymmetric allylation (see 10 --> 76) methodology are also noteworthy.

  DOI：

  10.1021/ja971946k

文献信息

• AZIRIDINYL-EPOTHILONE COMPOUNDS
  申请人：Vite D. Gregory

  公开号：US20070276018A1

  公开（公告）日：2007-11-29

  The present invention is directed to aziridinyl epothilone compounds as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof having the following Formula: wherein K is —O—, —S—, or —NR 7 —; A is —(CR 8 R 9 )—(CH 2 ) m -Z- wherein Z is —(CHR 10 )—, —C(═O)—, —C(═O)—C(═O)—, —OC(═O)—, —N(R 11 )C(═O)—, —SO 2 —, or —N(R 11 )SO 2 —; B 1 is hydroxyl or cyano and R 1 is hydrogen or B 1 and R 1 are taken together to form a double bond; R 2 , R 3 , and R 5 are, independently, hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; or R 2 and R 3 may be taken together with the carbon to which they are attached to form an optionally substituted cycloalkyl; R 4 is hydrogen, alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, or substituted aryl; R 6 is hydrogen, alkyl or substituted alkyl; R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl; and R 13 is aryl, substituted aryl, heteroaryl or substituted heteroaryl.

  本发明涉及如下所述的吲哚环毒毒素化合物，以及/或其在下式中具有以下结构的药学上可接受的盐和/或溶剂：其中K为—O—、—S—或—NR7—；A为—(CR8R9)—(CH2)m-Z-，其中Z为—(CHR10)—、—C(═O)—、—C(═O)—C(═O)—、—OC(═O)—、—N(R11)C(═O)—、—SO2—或—N(R11)SO2—；B1为羟基或氰基，R1为氢或B1和R1一起形成双键；R2、R3和R5独立地为氢、烷基、取代烷基、芳基或取代芳基；或R2和R3可以与它们连接的碳一起形成可选择取代的环烷基；R4为氢、烷基、烯烃基、取代烷基、取代烯烃基、芳基或取代芳基；R6为氢、烷基或取代烷基；R7、R8、R9、R10、R11和R12独立地为氢、烷基、取代烷基、环烷基、取代环烷基、芳基、取代芳基、杂环烷基、取代杂环烷基、杂芳基或取代杂芳基；而R13为芳基、取代芳基、杂芳基或取代杂芳基。
• CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Vite D. Gregory

  公开号：US20070275904A1

  公开（公告）日：2007-11-29

  The present invention is directed to conjugated compounds comprising a folate, or an analog or derivative thereof, and an aziridinyl epothilone analog, as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof, useful in the treatment of cancer or other folate-receptor associated conditions.

  本发明涉及包含叶酸、叶酸类似物或衍生物以及环氧紫杉烷类似物的共轭化合物，如下文进一步描述，并/或其药用可接受盐和/或溶剂，用于治疗癌症或其他叶酸受体相关疾病。
• The Olefin Metathesis Approach to Epothilone A and Its Analogues
  作者：K. C. Nicolaou、Y. He、D. Vourloumis、H. Vallberg、F. Roschangar、F. Sarabia、S. Ninkovic、Z. Yang、J. I. Trujillo

  DOI：10.1021/ja971109i

  日期：1997.8.1

  The olefin metathesis approach to epothilone A (1) and several analogues (39−41, 42−44, 51−57, 58−60, 64−65, and 67−69) is described. Key building blocks 6−8 were constructed in optically active form and were coupled and elaborated to olefin metathesis precursor 4 via an aldol reaction and an esterification coupling. Olefin metathesis of compound 4, under the catalytic influence of RuCl2(CHPh)(PCy3)2

  描述了埃坡霉素 A (1) 和几种类似物（39-41、42-44、51-57、58-60、64-65 和 67-69）的烯烃复分解方法。关键构建块 6-8 以旋光形式构建，并通过羟醛反应和酯化偶联与烯烃复分解前体 4 偶联和加工。在 RuCl2(CHPh)(PCy3)2 的催化作用下，化合物 4 的烯烃复分解反应提供顺式和反式环烯烃 3 和 48。49 的环氧化得到埃坡霉素 A (1) 和几种类似物，而 50 的环氧化得到在额外的埃坡霉素中。异构体和更简单的中间体的类似加工导致了另一系列埃坡霉素类似物和模型系统。
• PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS
  申请人：Parlanti Luca

  公开号：US20120178941A1

  公开（公告）日：2012-07-12

  A process for making aziridinyl epothilone compounds according to formula G, starting from a compound according formula C where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 12 , R 13 , Z 1 and Z 2 in formulae (G) and (C) are as defined herein. The aziridinyl epothilone compounds of formula (G) are useful for the treatment of cancer.

  一种制备式G的环氧乙烯酮化合物的方法，从式C的化合物开始，其中在式（G）和（C）中定义如下：R1、R2、R3、R4、R5、R6、R12、R13、Z1和Z2。式（G）中的环氧乙烯酮化合物对于癌症的治疗是有用的。
• Synthesis and Characterization of Upper and Lower Rim Functionalized [6]Cavitands
  作者：Christoph Naumann、Brian O. Patrick、John Sherman

  DOI：10.1002/1521-3765(20020816)8:16<3717::aid-chem3717>3.0.co;2-g

  日期：2002.8.16

  A [6]cavitand has been selectively derivatized on both the lower and upper rims. On the lower rim, two out of six potential sites were oxidized to produce a 1,4 substituted [6]cavitand bisketone, which was converted to a corresponding diol as well as a bisacetate [6]cavitand. The crystal structures of the bisketone and the diol were solved. On the upper rim, all six ArCH3 groups were selectively brominated to ArCH2Br groups to produce the hexabromomethyl [6]cavitand, which was converted to the corresponding hexabenzylthiol and hexabenzylthioacetate [6]cavitands. The conformational properties of all compounds are discussed.